Pending postmarket study commitments dropping

The FDA says 71% (899) of pending postmarketing study commitments promised by drug sponsors at the time of approval have never been started. This is a worsening trend; in 2005, 65% (797) of pending studies had not been started.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions